دورية أكاديمية
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
| العنوان: | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab |
|---|---|
| المؤلفون: | Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria, Brenner, Nicole, Kaehler, Katharina, Heinzerling, Lucie, Gutzmer, Ralf, Bender, Armin, Gebhardt, Christoffer, Romano, Emanuela, Meier, Friedegund, Martus, Peter, Maio, Michele, Blank, Christian, Schadendorf, Dirk, Dummer, Reinhard, Ascierto, Paolo A., Hospers, Geke, Garbe, Claus, Wolchok, Jedd D. |
| المصدر: | Weide , B , Martens , A , Hassel , J C , Berking , C , Postow , M A , Bisschop , K , Simeone , E , Mangana , J , Schilling , B , Di Giacomo , A M , Brenner , N , Kaehler , K , Heinzerling , L , Gutzmer , R , Bender , A , Gebhardt , C , Romano , E , Meier , F , Martus , P , Maio , M , Blank , C , Schadendorf , D , Dummer , R , Ascierto , P .... |
| سنة النشر: | 2016 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | CELL LUNG-CANCER, METASTATIC MELANOMA, LACTATE-DEHYDROGENASE, UNTREATED MELANOMA, PD-1 BLOCKADE, T-CELLS, IPILIMUMAB, NIVOLUMAB, SAFETY, RESPONSES |
| الوصف: | Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. Experimental Design: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan-Meier analysis and Cox regression were applied for survival analysis. Results: Relative eosinophil count (REC) >= 1.5%, relative lymphocyte count (RLC) >= 17.5%, Conclusions: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. (C)2016 AACR. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/2d96fa4d-f5e9-4fe9-9f75-e3a8c534f76dTest |
| DOI: | 10.1158/1078-0432.CCR-16-0127 |
| الإتاحة: | https://doi.org/10.1158/1078-0432.CCR-16-0127Test https://hdl.handle.net/11370/2d96fa4d-f5e9-4fe9-9f75-e3a8c534f76dTest https://research.rug.nl/en/publications/2d96fa4d-f5e9-4fe9-9f75-e3a8c534f76dTest |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.491DF673 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/1078-0432.CCR-16-0127 |
|---|